CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, i...
Phase 3
Louisville, Kentucky, United States and 109 other locations
of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple...
Phase 2
Louisville, Kentucky, United States and 51 other locations
provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...
Phase 2
Louisville, Kentucky, United States and 86 other locations
drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemothera...
Phase 1, Phase 2
Louisville, Kentucky, United States and 31 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
Louisville, Kentucky, United States and 265 other locations
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...
Phase 3
Louisville, Kentucky, United States and 181 other locations
Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...
Phase 3
Louisville, Kentucky, United States and 135 other locations
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple...
Phase 2
Louisville, Kentucky, United States and 8 other locations
out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab c...
Phase 1, Phase 2
Louisville, Kentucky, United States and 40 other locations
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma...
Phase 2
Louisville, Kentucky, United States and 76 other locations
Clinical trials
Research sites
Resources
Legal